Medline Inc. (MDLN) Stock: Price, Forecast & Analyst Target
Medline Inc. (MDLN) — MoonshotScore 72/100 (Strong band), calculated Nov 18, 2026. Price $37.84 (-3.37%), as of the Nov 19, 2026 trading session; market cap $49.8B.
Educational signal · not a buy or sell recommendation · How to read this
Medline Inc. · MDLN · NASDAQ · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-12: Medline manufactures its own medical and surgical supplies while also distributing outside brands and managing healthcare supply chains. Revenue continues to expand, but the defining test is whether stronger gross profit can reach operating and net income while overhead and debt absorb a large share of the economics.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Medline (MDLN)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Rising.
- EPS beat 0 of the last 4 reports
- Altman Z 2.15 · Piotroski F 8
- ROE 4.8% · ROA 2.7% · current ratio 4.04
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 74 | Strong | |
| 74 | Strong | |
| 72 | Strong | |
| 72 | Strong | |
| 72 | Strong | |
| 72 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $37.84 | |
| Change on the day | -3.37% | |
| 52-week range | $31.37–$50.88 | |
| Market capitalisation | $49.8B | — |
| Price / earnings (trailing) | 56.24 | |
| Shares traded on the day | 10.34M | |
| Beta (volatility vs the S&P 500) | -0.39 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Medline (MDLN): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Medline (MDLN), and what does it report?
Short answer · as of
Medline sells routine care supplies, surgical products, laboratory and diagnostic equipment, and infection-control goods to hospitals, surgical centers, physician practices, nursing homes, and other care facilities.
Research dated 2026-09-12.
Demand therefore comes from recurring clinical consumption as well as procedure activity, testing, and facility supply needs.
What do the latest results show for Medline (MDLN)?
Research dated 2026-09-12.
The latest period brought a revenue rebound and the highest gross profit in the presented series. Operating profit nevertheless edged lower and net income contracted sharply as selling, general, and administrative expense rose, so the improvement in product economics did not flow through to shareholders. Revenue and reported earnings exceeded estimates, while operating cash flow strengthened markedly.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Mar 2025 | $6.64B | $322M | — |
| Q4 FY2025 | $7.79B | $182M | $0.22 (diluted) |
| Q1 FY2026 | $7.35B | $129M | $0.16 (diluted) |
What are the financial strengths and risks for Medline (MDLN)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Cash has accumulated rapidly and recent operations have produced substantial cash, giving Medline ample near-term liquidity. Debt remains far above cash, however, leaving the company firmly in a net-debt position; strong liquidity ratios should not be mistaken for a lightly financed balance sheet.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 56.24 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Medline (MDLN)?
Short answer · as of
Current published price targets run low $37.00 · high $55.00 · consensus $44.20 · median $44.00 against a quoted price of $37.84 (as of Nov 19, 2026).
Research dated 2026-09-12.
Watch whether revenue growth continues to lift gross profit without another disproportionate rise in overhead. The relevant confirmation is renewed operating-income growth, better conversion into net income, and operating cash flow that remains strong enough to fund investment while cash continues closing the gap with debt.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Medline compare with its peers?
Short answer
Medline's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Medline is neither merely a medical-product manufacturer nor merely a distributor. Its proprietary supplies sit beside outside-brand sourcing, logistics consulting, warehousing support, inventory rationalization, specialized packaging, and route planning, creating a broader relationship with care providers than a product-only supplier would have.
| Company | Price | Market value | Score |
|---|---|---|---|
| $242.61 Nov 18, 2026 | $34.1B | 95 5-pillar Nov 18, 2026 | |
| $420.95 Nov 18, 2026 | $146B | 94 5-pillar Nov 18, 2026 | |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| $120.37 Nov 19, 2026 | $5.48B | 83 5-pillar Nov 18, 2026 | |
| $84.41 Nov 19, 2026 | $5.06B | 81 5-pillar Nov 18, 2026 | |
| $74.52 Nov 19, 2026 | $35.8B | 80 5-pillar Nov 18, 2026 | |
| $140.34 Nov 19, 2026 | $8.90B | 77 5-pillar Nov 18, 2026 | |
| $175.76 Nov 19, 2026 | $4.40B | 73 5-pillar Nov 18, 2026 | |
| Medline (MDLN) — this page | $37.84 | $49.8B | 72 |
| $15.12 Nov 19, 2026 | $10.3B | 71 5-pillar Nov 18, 2026 | |
| $170.29 Nov 19, 2026 | $10.9B | 71 5-pillar Nov 18, 2026 | |
| $212.73 Nov 19, 2026 | $57.9B | 68 5-pillar Nov 18, 2026 | |
| $163.40 Nov 19, 2026 | $6.48B | 61 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $37.00 – $55.00
- Consensus target
- $44.20
- Median target
- $44.00
Consensus record · Captured .
Measured against a quoted price of $37.84 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 8, 2026
- Transactions
- 22
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 16
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MDLN in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | Q3 2026 | 0% | $0 | Sold out (was $190.93M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Medline (MDLN)?
What Investors Ask About Medline (MDLN) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do Medline Brand and Supply Chain Solutions differ?
Medline Brand manufactures or sources proprietary clinical products spanning frontline care, surgery, laboratories, and diagnostics. Supply Chain Solutions distributes outside brands and provides logistics, warehousing, inventory, packaging, and route-planning services.
Why can Medline sales rise while earnings weaken?
Recent revenue and gross profit increased, but higher selling, general, and administrative expense prevented that improvement from reaching operating profit and net income. The key mechanism is therefore expense absorption, not merely sales growth.
What matters about Medline’s Tracy and Stockton facilities?
Tracy is already occupied and management expects it to begin serving customers later in the calendar, while Stockton occupancy is planned after the calendar turns. Their importance lies in whether added distribution capacity supports service and growth without keeping overhead elevated.
Does Medline’s growing cash balance remove its debt pressure?
Cash has risen rapidly, but it remains well below total debt, leaving substantial net debt. Recent cash generation improves flexibility without eliminating the leverage burden.
What is the MDLN stock price today?
The last price recorded for Medline Inc. (MDLN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MDLN price target?
The analyst consensus price target for Medline Inc. (MDLN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com